MHC-HE454-100μg / 询价
MHC-HE454-500μg / 询价
MHC-HE454-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein
Recombinant Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide [Accession | NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAVGVGK].
The protein has a predicted MW of 35.26 kDa (HLA-A*03:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
